Dr. George Syrmalis, MD, PhD, is a physician and entrepreneur with extensive expertise in nuclear medicine, radiation immunology, and biotechnology. He is the founder and CEO of Bioscience Equity Partners; a global investment bank and fund manager focused on early stage biotech and med-tech innovations. His career spans founding multiple companies, leading IPOs, and advancing translational medicine and theranostics.

Extensive leadership in biotech investment: George Syrmalis leads Bioscience Equity Partners, operating globally with offices in major cities, focusing exclusively on life sciences investments and venture capital for early-stage startups.

Entrepreneurial ventures and IPO successes: He founded the iQ Group Global and has been instrumental in incubating and growing several biotech companies, overseeing more than twelve IPOs on exchanges including ASX, NSX, NASDAQ, and European markets. He was also the founder of Biotechs Antisoma and the Bionuclear Group in 1995.

Medical and research background: Syrmalis holds an M.D. and Ph.D. from the University of California, is a Fellow of the Royal Society of Medicine, and has experience in nuclear medicine and radiopharmaceutical translational research, having served in clinical and executive roles across Europe, the US, and Saudi Arabia.